Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000343327

Medchemexpress LLC Thiazolo[5,4-f]quinazoline-2-carboximidic acid, 9-[(2-fluoro-4-methoxyphenyl)amino]-, methyl ester | 1425945-60-3 | 98.9% | 383.40 | 50 MG
SDP

Catalog No. 5000343327
Encompass_Preferred

EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A) and 0.59 nM (DYRK1B). It exhibits antileukemia effect, regulates cell cycle, and induces cell apoptosis.

  • Induces apoptosis of primary ALL cells that were resistant to cytarabine.
  • Dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric cells.
  • Inhibits DYRK1A, leading to a loss of DYRK1A-mediated FOXO1 and STAT3 signaling, resulting in preferential cell death in leukemic B cells.
  • Inhibits phosphorylation of FOXO1, STAT3, and cyclin D3, regulating late cell-cycle progression, mitochondrial ROS, and DNA damage.
  • Demonstrates antileukemia activity in a leukemic aggressive model in mice, reducing leukemic burden and conferring a modest survival advantage.

Catalog No. 50-003-43327 Supplier Medchemexpress LLC Supplier No. HY11138050MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

EHT 1610 is a potent inhibitor of DYRK, with IC50s of 0.36 nM (DYRK1A) and 0.59 nM (DYRK1B). It exhibits antileukemia effect, regulates cell cycle, and induces cell apoptosis.

  • Induces apoptosis of primary ALL cells that were resistant to cytarabine.
  • Dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric cells.
  • Inhibits DYRK1A, leading to a loss of DYRK1A-mediated FOXO1 and STAT3 signaling, resulting in preferential cell death in leukemic B cells.
  • Inhibits phosphorylation of FOXO1, STAT3, and cyclin D3, regulating late cell-cycle progression, mitochondrial ROS, and DNA damage.
  • Demonstrates antileukemia activity in a leukemic aggressive model in mice, reducing leukemic burden and conferring a modest survival advantage.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.